About this item
Product details
Glem-Lin MXR from Nabiqasim represents an advanced triple-combination therapy for comprehensive Type 2 Diabetes management. Each extended-release tablet contains three proven medications: Empagliflozin 10 mg (SGLT2 inhibitor), Linagliptin 5 mg (DPP-4 inhibitor), and Metformin 1000 mg (Biguanide). This powerful formulation addresses multiple pathways of glucose control simultaneously, offering robust glycemic management in a single, convenient once-daily tablet for patients requiring intensive treatment. Triple-Action Therapy: Combines three complementary mechanisms for superior blood sugar control Comprehensive Glucose Management: Metformin reduces liver glucose production and improves insulin sensitivity Linagliptin increases insulin release and decreases glucagon production Empagliflozin removes excess glucose through urine Extended-Release Formulation: The MXR version provides sustained Metformin delivery for better gastrointestinal tolerance Cardiovascular & Renal Benefits: Empagliflozin component offers proven cardiovascular risk reduction and kidney protection Convenient Regimen: Single once-daily tablet simplifies complex medication schedules Composition Each film coated tablet contains: Empagliflozin : 10 mg Linagliptin: 5 mg Metformin HCI USP (as extended release core): 1000 mg Suggested Usage As directed by the physician
- Medicines
- 14 Film Coated Tablets
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Nabiqasim
- SKU
- 08964003524210
- Variant
- 14 Film Coated Tablets
- Tags
- Empagliflozin, Linagliptin, Medicine, Metformin
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
